Patents by Inventor Joan R. Kanter

Joan R. Kanter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
    Patent number: 8114590
    Abstract: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: February 14, 2012
    Assignee: The Regents of the University of California
    Inventors: Paul A. Insel, Lingzhi Zhang, Fionna Murray, Joan R. Kanter, Thomas Kipps, Laura Rassenti
  • Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)
    Publication number: 20110117562
    Abstract: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
    Type: Application
    Filed: December 6, 2010
    Publication date: May 19, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Paul A. Insel, Lingzhi Zhang, Fionna Murray, Joan R. Kanter, Thomas Kipps, Laura Rassenti
  • Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
    Patent number: 7846664
    Abstract: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: December 7, 2010
    Assignee: The Regents of the University of California
    Inventors: Paul A. Insel, Lingzhi Zhang, Fiona Murray, Joan R. Kanter, Thomas Kipps, Laura Rassenti
  • Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)
    Publication number: 20090131353
    Abstract: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
    Type: Application
    Filed: December 7, 2006
    Publication date: May 21, 2009
    Inventors: Paul A. Insel, Lingzhi Zhang, Fiona Murray, Joan R. Kanter, Thomas Kipps, Laura Rassenti